Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Melanoma Stage IV, Solid Tumor
In brief
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Key facts
- Study ID
- NCT06425926
- Run by
- Georgiamune Inc
- People needed
- 117
- Starts
- 2024-05-09
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-03-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States (enrolling)
- Comprehensive Blood and Cancer Center — Bakersfield, California, United States (enrolling)
- Providence Medical Foundation — Fullerton, California, United States (enrolling)
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California, United States (enrolling)
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana — Billings, Montana, United States (enrolling)
- Weill Cornell Medicine - New York Presbyterian Hospital — New York, New York, United States (enrolling)
- University of Cincinnati Cancer Center — Cincinnati, Ohio, United States (enrolling)
- Tennessee Oncology, PLLC — Nashville, Tennessee, United States (enrolling)
- Virginia Commonwealth University — Richmond, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.